BioCision Announces the Formation of MedCision

New Company will Focus on Technologies for the Management and Automation of Vital Clinical Processes

SAN RAFAEL, Calif.--()--BioCision, LLC, a life science research and development company that standardizes basic laboratory processes, today announced the formation of MedCision, Inc., an independent company focused on automation of pre-clinical and clinical processes.

“The formation of MedCision is driven by a critical need in the market – innovative, standardization technologies and solutions for translational, clinical and point-of-care settings,” said Rolf O. Ehrhardt, MD, PhD, BioCision CEO. “MedCision will be a leader in developing and commercializing innovative instruments for crucial processes in the post-manufacturing cell and gene therapy space.”

Dr. Ehrhardt continued, “The name of the company, MedCision, creates a clear connection to our BioCision roots but also conveys an evolution from those roots as our technology will focus on automating point-of-care clinical processes.”

The creation of MedCision as a stand-alone company with a dedicated management team will provide the necessary focus and foundation for long-term value generation in the clinical tools space. Commercialization of the award-winning ThawSTAR® cell thawing platform will initially be the focus of MedCision.

Cell thawing, the last step a cellular product undergoes before patient administration, is one of the most important parts of the post manufacturing process. Rapid, uniform, non-fluid based thawing is necessary to maintaining therapeutic efficacy. ThawSTAR’s automated cell thawing platform makes it easy to ensure proper clinical handling and thawing across a range of volumes and storage formats. At the same time, the platform automatically incorporates temperature monitoring and data connectivity, both of which are critical to ensuring proper sample tracking and patient safety.

The ThawSTAR platform is experiencing rapid adoption into cell therapy research and development as part of clinical trials and will accelerate with the soon-to-be-announced Early Adopter Program. As the flagship product of this new company, the ThawSTAR platform will be expanded over the next 12 months with additional models and features.

MedCision corporate offices will be headquartered in San Rafael, California and spearheaded by former members of the BioCision senior management team. Rolf Ehrhardt, will serve as President and CEO, Ron DiNocco, Chief Financial Officer and VP of Corporate Development, Eric Kunkel, SVP of Research and Development and Sam Kent, SVP Global Sales and Business Development.

For more information about MedCision, visit For business and partnership information, contact Samuel Kent at

About MedCision

Through cutting edge science, engineering and software, MedCision develops and commercializes standardization and automation technologies for vital preclinical and clinical sample handling. MedCision’s instrumentation will advance near patient drug management by providing controlled and scalable processing of temperature-sensitive products.

About BioCision

BioCision is a research and development company that provides passive tools to standardize critical processes throughout the life science industry. BioCision’s products can be integrated throughout research, development and manufacturing workflows, enabling consistent temperature control for sensitive biological samples. By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development.


Marla Kertzman, 209-852-9027

Release Summary

BioCision Announces the Formation of MedCision. The New Company will Focus on Technologies for the Management and Automation of Vital Clinical Processes.


Marla Kertzman, 209-852-9027